Hypoxia imaging markers and applications for radiation treatment planning

Seminars in Nuclear Medicine

Volumn 42, Issue 5, 2012, Pages 343-352

  Lin, Alexander ^a   Hahn, Stephen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

18F 2 (2 NITRO 1H IMIDAZOL 1 YL) N(2,2,3,3,3 PENTAFLUOROPROPYL) ACETAMIDE; 18F FLUOROAZAMYCIN ARABINOSIDE; 18F FLUOROERYTHROMNITROIMIDAZOLE; 18F FLUOROMIXONIDAZOLE; COPPER DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE); HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOMYCIN C; PROTEIN P53; RADIOPHARMACEUTICAL AGENT; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CONTROL; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DNA STRAND BREAKAGE; DRUG BINDING; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; OROPHARYNX CANCER; OVERALL SURVIVAL; OXYGENATION; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SIGNAL NOISE RATIO; TREATMENT OUTCOME; TREATMENT PLANNING; UTERINE CERVIX CANCER; WART VIRUS;

EID: 84864400472     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2012.04.002     Document Type: Review

References (94)

1. L.H. Gray, A.D. Conger, M. Ebert The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy Br J Radiol 26 1953 638 648
2. R.H. Thomlinson, L.H. Gray The histological structure of some human lung cancers and the possible implications for radiotherapy Br J Cancer 9 1955 539 549
3. P. Vaupel, D.K. Kelleher, M. Hockel Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy Semin Oncol 28 suppl 8 2001 29 35
4. J.D. Chapman, D.L. Dugle, A.P. Reuvers Letter: Studies on the radiosensitizing effect of oxygen in Chinese hamster cells Int J Radiat Biol Relat Stud Phys Chemo Med 26 1974 383 389
5. G. Powis, L. Kirkpatrick Hypoxia inducible factor-1α as a cancer drug target Mol Cancer Ther 3 2004 647 654
6. V.E. Belozerov, E.G. Van Meir Hypoxia inducible factor-1: A novel target for cancer therapy Anticancer Drugs 16 2005 901 909
7. P. Vaupel The role of hypoxia-induced factors in tumor progression Oncologist 9 suppl 5 2004 10 17
8. G.L. Semenza Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis J Lab Clin Med 131 1998 207 214
9. P. Vaupel Tumor microenvironmental physiology and its implications for radiation oncology Semin Radiat Oncol 14 2004 198 206
10. D.R. Ciocca, S.K. Calderwood Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications Cell Stress Chaperones 10 2005 86 103
11. 2 tension measurements Cancer Res 51 1991 3316 3322
12. M. Höckel, P. Vaupel Biological consequences of tumor hypoxia Semin Oncol 28 suppl 8 2001 36 41
13. M. Hockel, K. Schlenger, B. Aral Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 1996 4509 4515
14. A. Fyles, M. Milosevic, D. Hedley Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer J Clin Oncol 20 2002 680 687
15. D.M. Brizel, G.S. Sibley, L.R. Prosnitz Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck Int J Radiat Oncol Biol Phys 38 1997 285 289
16. M. Nordsmark, S.M. Bentzen, V. Rudat Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy An international multi-center study Radiother Oncol 77 2005 18 24
17. D.M. Brizel, S.P. Scully, J.M. Harrelson Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res 56 1996 941 943
18. M. Nordsmark, J. Alsner, J. Keller Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations Br J Cancer 84 2001 1070 1075
19. I. Churchill-Davidson The oxygen effect in radiotherapy - Historical review Front Radiat Ther Oncol 1 1968 1 15
20. J.M. Henk, P.B. Kunkler, C.W. Smith Radiotherapy and hyperbaric oxygen in head and neck cancer Final report of first controlled clinical trial Lancet 2 1977 101 103
21. J.M. Henk, C.W. Smith Radiotherapy and hyperbaric oxygen in head and neck cancer Interim report of second clinical trial Lancet 2 1977 104 105
22. E.R. Watson, K.E. Halnan, S. Dische Hyperbaric oxygen and radiotherapy: A medical research council trial in carcinoma of the cervix Br J Radiol 51 1978 879 887
23. I.S. Cade, J.B. McEwen, S. Dische Hyperbaric oxygen and radiotherapy: A medical research council trial in carcinoma of the bladder Br J Radiol 51 1978 876 878
24. J. Overgaard Sensitization of hypoxic tumour cells - Clinical experience Int J Radiat Biol 56 1989 801 811
25. J. Overgaard, H.S. Hansen, A.P. Andersen Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study Int J Radiat Oncol Biol Phys 16 1989 1065 1068
26. J. Overgaard Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors Oncol Res 6 1994 509 518
27. D.J. Lee, D. Cosmatos, V.A. Marcial Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas Int J Radiat Oncol Biol Phys 32 1995 567 576
28. S. Dische, D. Machin, D. Chassagne A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: An interim report from the medical research council working party on advanced carcinoma of the cervix Radiother Oncol 26 1993 93 103
29. J. Overgaard, H.S. Hansen, M. Overgaard A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 Radiother Oncol 46 1998 135146
30. J.B. Weissberg, Y.H. Son, R.J. Papac Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer Int J Radiat Oncol Biol Phys 17 1989 3 9
31. B.G. Haffty, Y.H. Son, C.T. Sasaki Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials Int J Radiat Oncol Biol Phys 27 1993 241 250
32. W. Dobrowsky, J. Naudé, E. Dobrowsky Mitomycin C (MMC) and unconventional fractionation (V-CHART) in advanced head and neck cancer Acta Oncol 34 1995 270 272
33. C. Grau, P.J. Agarwal, K. Jabeen Radiotherapy with or without mitomycin C in the treatment of locally advanced head and neck cancer: Results of the IAEA multicentre randomised trial Radiother Oncol 67 2003 17 26
34. D. Rischin, L. Peters, R. Fisher Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02) J Clin Oncol 23 2005 79 87
35. D. Rischin, L.J. Peters, B. O'Sullivan Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the trans-tasman radiation oncology group J Clin Oncol 28 2010 2989 2995
36. D. Rischin, R.J. Young, R. Fisher Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial J Clin Oncol 28 2010 4142 4148
37. K.K. Ang, J. Harris, R. Wheeler Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 2010 24 35
38. J.G. Rajendran, K.R. Hendrickson, A.M. Spence Hypoxia imaging-directed radiation treatment planning Eur J Nucl Med Mol Imaging 33 suppl 1 2006 44 53
39. M. Kikuchi, T. Yamane, S. Shinohara 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma Ann Nucl Med 25 2011 625 633
40. D. Rischin, R.J. Hicks, R. Fisher Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2006 2098 2104
41. D. Thorwarth, S.M. Eschmann, J. Scheiderbauer Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer BMC Cancer 5 2005 152
42. S.M. Eschmann, F. Paulsen, M. Reimold Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy J Nucl Med 46 2005 253 260
43. J.G. Rajendran, D.L. Schwartz, J. O'Sullivan Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer Clin Cancer Res 12 2006 5435 5441
44. F. Hugonnet, L. Fournier, J. Medioni Metastatic renal cell carcinoma: Relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: An 18F-fluoromisonidazole PET/CT study J Nucl Med 52 2011 1048 1055
45. A.M. Spence, M. Muzi, K.R. Swanson Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: Correlation with time to progression and survival Clin Cancer Res 14 2008 2623 2630
46. L. Li, M. Hu, H. Zhu Comparison of 18F-fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer Clin Lung Cancer 11 2010 335 340
47. F. Dehdashti, M.A. Mintun, J.S. Lewis In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM Eur J Nucl Med Mol Imaging 30 2003 844 850
48. D.W. Dietz, F. Dehdashti, P.W. Grigsby Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: A pilot study Dis Colon Rectum 51 2008 1641 1648
49. Y. Minagawa, K. Shizukuishi, I. Koike Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: A pilot study Ann Nucl Med 25 2011 339 345
50. F. Dehdashti, P.W. Grigsby, M.A. Mintun Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response-a preliminary report Int J Radiat Oncol Biol Phys 55 2003 1233 1238
51. F. Dehdashti, P.W. Grigsby, J.S. Lewis Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4- methylthiosemicarbazone) J Nucl Med 49 2008 201 205
52. T. Yamane, M. Kikuchi, S. Shinohara Reduction of [(18)F] fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma Mol Imaging Biol 13 2011 227 231
53. S.M. Eschmann, F. Paulsen, C. Bedeshem Hypoxia-imaging with (18)F-misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer Radiother Oncol 83 2007 406 410
54. W.J. Koh, K.S. Bergman, J.S. Rasey Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography Int J Radiat Oncol Biol Phys 33 1995 391 398
55. N. Lee, S. Nehmeh, H. Schöder Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy Int J Radiat Oncol Biol Phys 75 2009 101 108
56. R.J. Hicks, D. Rischin, R. Fisher Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent Eur J Nucl Med Mol Imaging 32 2005 1384 1391
57. S.A. Nehmeh, N.Y. Lee, H. Schröder Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer Int J Radiat Oncol Biol Phys 70 2008 235 242
58. E.M. Lord, L. Harwell, C.J. Koch Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts Cancer Res 53 1993 5271 5276
59. S.M. Evans, S. Hahn, D.R. Pook Detection of hypoxia in human squamous cell carcinoma by EF5 binding Cancer Res 60 2000 2018 2024
60. S.M. Evans, D. Fraker, S.M. Hahn EF5 binding and clinical outcome in human soft tissue sarcomas Int J Radiat Oncol Biol Phys 64 2006 922 927
61. S.M. Evans, K.L. Du, A.A. Chalian Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome Int J Radiat Oncol Biol Phys 69 2007 1024 1031
62. S.M. Evans, K.D. Judy, I. Dunphy Hypoxia is important in the biology and aggression of human glial brain tumors Clin Cancer Res 10 2004 8177 8184
63. S.M. Evans, K.W. Jenkins, H.I. Chen The relationship among hypoxia, proliferation, and outcome in patients with de novo glioblastoma: A pilot study Transl Oncol 3 2010 160 169
64. D. Marotta, J. Karar, W.T. Jenkins In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection Cancer Res 71 2011 779 789
65. C.J. Koch, J.S. Scheuermann, C. Divgi Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastomas Eur J Nucl Med Mol Imaging 37 2010 2048 2059
66. K. Lehtiö, V. Oikonen, T. Grönroos Imaging of blood flow and hypoxia in head and neck cancer: Initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET J Nucl Med 42 2001 1643 1652
67. K. Lehtiö, O. Eskola, T. Viljanen Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer Int J Radiat Oncol Biol Phys 59 2004 971 982
68. 18 F-FETNIM PET in esophageal squamous cell carcinoma: A pilot clinical study Dis Esophagus 25 2012 54 61
69. T. Grönroos, L. Bentzen, P. Marjamäki Comparsion of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma Eur J Nucl Med Mol Imaging 31 2004 513 520
70. H. Barthel, H. Wilson, D.R. Collingridge In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography Br J Cancer 90 2004 2232 2242
71. J.S. Rasey, P.D. Hofstrand, L.K. Chin Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia J Nucl Med 40 1999 1072 1079
72. R. Garcia-Parra, D. Wood, R.B. Shah Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques Eur J Nucl Med Mol Imaging 38 2011 1816 1823
73. M. Schuetz, M.P. Schmid, R. Pötter Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer Acta Oncol 49 2010 941 947
74. E.J. Postema, A.J. McEwan, T.A. Riauka Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA) Eur J Nucl Med Mol Imaging 36 2009 1565 1573
75. M. Souvatzoglou, A.L. Grosu, B. Röper Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: A pilot study Eur J Nucl Med Mol Imaging 34 2007 1566 1575
76. M. Piert, H.J. Machulla, M. Picchio Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside J Nucl Med 46 2005 106 113
77. 3 H-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia J Labelled Comp Radiopharm 42 1999 3 16
78. Y. Fujibayashi, H. Taniuchi, Y. Yonekura Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential J Nucl Med 38 1997 1155 1160
79. J.L. Dearling, J.S. Lewis, G.E. Mullen Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro Eur J Nucl Med 25 1998 788 792
80. J.S. Lewis, D.W. McCarthy, T.J. McCarthy Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model J Nucl Med 40 1999 177 183
81. J.S. Lewis, T.L. Sharp, R. Laforest Tumor uptake of copper-diacetyl- bis(N(4)-methylthiosemicarbazone): Effect of changes in tissue oxygenation J Nucl Med 42 2001 655 661
82. J.S. Lewis, P. Herrero, T.L. Sharp Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) J Nucl Med 43 2002 1557 1569
83. H. Yuan, T. Schroeder, J.E. Bowsher Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4- methylthiosemicarbazone) J Nucl Med 47 2006 989 998
84. P.W. Grigsby, R.S. Malyapa, R. Higashikubo Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix Mol Imaging Biol 9 2007 278 283
85. J.S. Lewis, R. Laforest, F. Dehdashti An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix J Nucl Med 49 2008 1177 1182
86. K. Hendrickson, M. Phillips, W. Smith Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity-modulated radiation therapy in overcoming hypoxia-induced treatment resistance Radiother Oncol 101 2011 369 375
87. I. Toma-Dasu, J. Uhrdin, L. Antonovic Dose prescription and treatment planning based on FMISO-PET hypoxia Acta Oncol 51 2012 222 230
88. W. Choi, S.W. Lee, S.H. Park Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer Radiother Oncol 97 2010 176 182
89. P. Dirix, V. Vandecaveye, F. de Keyzer Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI J Nucl Med 50 2009 1020 1027
90. Z. Lin, J. Mechalakos, S. Nehmeh The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography Int J Radiat Oncol Biol Phys 70 2008 1219 1228
91. N.Y. Lee, J.G. Mechalakos, S. Nehmeh Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study Int J Radiat Oncol Biol Phys 70 2008 2 13
92. A.L. Grosu, M. Souvatzoglou, B. Röper Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer Int J Radiat Oncol Biol Phys 69 2007 541 551
93. E. Dalah, D. Bradley, A. Nisbet Simulation of tissue activity curves of (64)Cu-ATSM for sub-target volume delineation in radiotherapy Phys Med Biol 55 2010 681 694
94. K.S. Chao, W.R. Bosch, S. Mutic A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy Int J Radiat Oncol Biol Phys 49 2001 1171 1182